Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.

Sood A, Duseja A, Kabrawala M, Amrose P, Goswami B, Chowdhury A, Sarin SK, Koshy A, Hyland RH, Lu S, Camus G, Stamm LM, Brainard DM, Subramanian GM, Prasad M, Bhatia S, Shah SR, Kapoor D, Shalimar, Saraswat V.

Hepatol Int. 2019 Mar;13(2):173-179. doi: 10.1007/s12072-019-09927-6. Epub 2019 Feb 21.

2.

In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir.

Han B, Parhy B, Zhou E, Hsieh D, Camus G, Martin R, Svarovskaia ES, Mo H, Dvory-Sobol H.

J Clin Microbiol. 2019 Mar 28;57(4). pii: e01844-18. doi: 10.1128/JCM.01844-18. Print 2019 Apr.

PMID:
30728196
3.

Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.

Gupta N, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi CM, Shumbusho F, Musabeyezu E, Mukabatsinda C, Ntirenganya C, Van Nuil JI, Kateera F, Camus G, Damascene MJ, Nsanzimana S, Mukherjee J, Grant PM.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126. doi: 10.1016/S2468-1253(18)30382-0. Epub 2018 Dec 11.

PMID:
30552056
4.

Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support.

Henry A, Tourbah A, Camus G, Deschamps R, Mailhan L, Castex C, Gout O, Montreuil M.

Mult Scler Relat Disord. 2019 Jan;27:46-51. doi: 10.1016/j.msard.2018.09.039. Epub 2018 Oct 2.

PMID:
30317070
5.

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.

Sarrazin C, Cooper CL, Manns MP, Reddy KR, Kowdley KV, Roberts SK, Dvory-Sobol H, Svarovskia E, Martin R, Camus G, Doehle BP, Stamm LM, Hyland RH, Brainard DM, Mo H, Gordon SC, Bourliere M, Zeuzem S, Flamm SL.

J Hepatol. 2018 Dec;69(6):1221-1230. doi: 10.1016/j.jhep.2018.07.023. Epub 2018 Aug 9.

PMID:
30098373
6.

Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.

Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M.

Hepatol Int. 2018 Jul;12(4):356-367. doi: 10.1007/s12072-018-9878-6. Epub 2018 Jul 20.

7.

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

Esteban R, Pineda JA, Calleja JL, Casado M, Rodríguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrión JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M.

Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.

PMID:
29958855
8.

Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.

Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X.

J Hepatol. 2018 Sep;69(3):603-607. doi: 10.1016/j.jhep.2018.05.039. Epub 2018 Jun 8.

PMID:
29886154
9.

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.

Wei L, Xie Q, Hou JL, Tang H, Ning Q, Cheng J, Nan Y, Zhang L, Li J, Jiang J, McNabb B, Zhang F, Camus G, Mo H, Osinusi A, Brainard DM, Gong G, Mou Z, Wu S, Wang G, Hu P, Gao Y, Jia J, Duan Z.

Hepatol Int. 2018 Mar;12(2):126-132. doi: 10.1007/s12072-018-9856-z. Epub 2018 Apr 10.

10.

Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.

Camus G, Xu S, Han B, Lu J, Dvory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H.

Virology. 2018 Jan 15;514:134-141. doi: 10.1016/j.virol.2017.11.003. Epub 2017 Nov 22.

11.

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.

Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, Chang TT, Massetto B, Yang JC, Yun C, Knox SJ, Osinusi A, Camus G, Jiang D, Brainard DM, McHutchison JG, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ.

Gastroenterology. 2018 Mar;154(4):989-997. doi: 10.1053/j.gastro.2017.11.011. Epub 2017 Nov 22.

PMID:
29174546
12.

Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.

Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS Jr; RESCUE and ACTG A5348 study investigators.

Liver Int. 2018 Jun;38(6):1010-1021. doi: 10.1111/liv.13616. Epub 2017 Dec 5.

13.

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.

Camus G, Han B, Asselah T, Hsieh D, Dvory-Sobol H, Lu J, Svarovskaia E, Martin R, Parhy B, Miller MD, Brainard DM, Kersey K, Abergel A, Mo H.

J Viral Hepat. 2018 Feb;25(2):134-143. doi: 10.1111/jvh.12795. Epub 2017 Nov 7.

PMID:
28984067
14.

SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency.

Boehm D, Jeng M, Camus G, Gramatica A, Schwarzer R, Johnson JR, Hull PA, Montano M, Sakane N, Pagans S, Godin R, Deeks SG, Krogan NJ, Greene WC, Ott M.

Cell Host Microbe. 2017 May 10;21(5):569-579.e6. doi: 10.1016/j.chom.2017.04.011.

15.

Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.

Welzel TM, Bhardwaj N, Hedskog C, Chodavarapu K, Camus G, McNally J, Brainard D, Miller MD, Mo H, Svarovskaia E, Jacobson I, Zeuzem S, Agarwal K.

J Hepatol. 2017 Aug;67(2):224-236. doi: 10.1016/j.jhep.2017.03.014. Epub 2017 Mar 24.

PMID:
28343981
16.

[Photodegradation of chlorpromazine, a drug-related adverse event].

Chabi Y, Brahim K, Da Costa M, Caffin AG, Camus G, Paillet M, Bohand X.

Soins. 2016 Apr;(804):34-6. doi: 10.1016/j.soin.2016.02.006. French.

17.

[Individualized pharmaceutical consultations in the management of chemotherapy-induced nausea and vomiting].

Monfort AS, Vallin S, Te Bonle FO, Camus G, Gaveau R, Bohand X.

J Pharm Belg. 2015 Jun;(2):30-6. French.

PMID:
26466507
18.

[A training medication errors room: simulate to better train health professionals].

Joret-Descout P, Te Bonle F, Demange C, Bechet M, Da Costa M, Camus G, Bohand X.

J Pharm Belg. 2015 Jun;(2):10-9. French.

PMID:
26466505
19.

The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid droplets.

Camus G, Schweiger M, Herker E, Harris C, Kondratowicz AS, Tsou CL, Farese RV Jr, Herath K, Previs SF, Roddy TP, Pinto S, Zechner R, Ott M.

J Biol Chem. 2014 Dec 26;289(52):35770-80. doi: 10.1074/jbc.M114.587816. Epub 2014 Nov 7.

20.

[Preparation and administration of injectable antibiotics: a tool for nurses].

Guillaudin M, Griveaux A, Te Bonle F, Jandard V, Paillet M, Camus G, Galvez O, Bohand X.

Rev Infirm. 2013 Dec;(196):38-40. French.

PMID:
24427920
21.

Lipid droplets and viral infections.

Camus G, Vogt DA, Kondratowicz AS, Ott M.

Methods Cell Biol. 2013;116:167-90. doi: 10.1016/B978-0-12-408051-5.00009-7.

PMID:
24099293
22.

[Results and lessons of an innovating chemotherapy-induced nauseas and vomiting management strategy].

Jandard V, Guillaudin M, Bédrossian S, Breton D, Camus G, Paillet M, Rivière F, Le Floch H, Reignier S, Rimlinger H, Hervouet M, Vaylet F, Margery J, Bohand X.

Bull Cancer. 2013 Sep;100(9):799-810. doi: 10.1684/bdc.2013.1797. Review. French.

PMID:
23917624
23.

How the antiviral immune response boosts liver fat.

Camus G, Ott M.

Nat Med. 2013 Jun;19(6):671-2. doi: 10.1038/nm.3226. No abstract available.

PMID:
23744144
24.

Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein.

Vogt DA, Camus G, Herker E, Webster BR, Tsou CL, Greene WC, Yen TS, Ott M.

PLoS Pathog. 2013;9(4):e1003302. doi: 10.1371/journal.ppat.1003302. Epub 2013 Apr 11.

25.

[Review of medication errors: a case in an intensive care unit].

Guillaudin M, Debien B, Aouadene F, Camus G, Galvez O, Paillet M, Bohand X.

Ann Fr Anesth Reanim. 2013 May;32(5):285-90. doi: 10.1016/j.annfar.2013.02.011. Epub 2013 Apr 4. French.

PMID:
23562419
26.

Diacylglycerol acyltransferase-1 localizes hepatitis C virus NS5A protein to lipid droplets and enhances NS5A interaction with the viral capsid core.

Camus G, Herker E, Modi AA, Haas JT, Ramage HR, Farese RV Jr, Ott M.

J Biol Chem. 2013 Apr 5;288(14):9915-23. doi: 10.1074/jbc.M112.434910. Epub 2013 Feb 18.

27.

[The nurse as the last line of defence against quality defects in medicines].

Guillaudin M, Galvez O, Jandard V, Camus G, Paillet M, Bohand X.

Rev Infirm. 2012 May;(181):42-4. French.

PMID:
22670465
28.

Rab7A is required for efficient production of infectious HIV-1.

Caillet M, Janvier K, Pelchen-Matthews A, Delcroix-Genête D, Camus G, Marsh M, Berlioz-Torrent C.

PLoS Pathog. 2011 Nov;7(11):e1002347. doi: 10.1371/journal.ppat.1002347. Epub 2011 Nov 3.

29.

[Role of the hospital pharmacist in the management of chemotherapy-induced nausea and vomiting].

Breton D, Jandard V, Cauet A, Paillet M, Galvez O, Faure A, Camus G, Beltrando X, Rimlinger H, Hervouet M, Margery J, Bohand X, Vaylet F.

J Pharm Belg. 2011 Jun;(2):46-50. French. No abstract available.

PMID:
21823442
30.

Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model.

Bente DA, Alimonti JB, Shieh WJ, Camus G, Ströher U, Zaki S, Jones SM.

J Virol. 2010 Nov;84(21):11089-100. doi: 10.1128/JVI.01383-10. Epub 2010 Aug 25.

31.

Endosomal trafficking of HIV-1 gag and genomic RNAs regulates viral egress.

Molle D, Segura-Morales C, Camus G, Berlioz-Torrent C, Kjems J, Basyuk E, Bertrand E.

J Biol Chem. 2009 Jul 17;284(29):19727-43. doi: 10.1074/jbc.M109.019844. Epub 2009 May 18.

32.

WITHDRAWN: Annales de l'Institut Pasteur.

Camus G.

Res Microbiol. 2007 Oct 25. [Epub ahead of print]

PMID:
18995991
33.

[Celiac disease associated with antiphospholipid syndrome].

Jorge O, Jorge A, Camus G.

Rev Esp Enferm Dig. 2008 Feb;100(2):102-3. Spanish.

34.

The clathrin adaptor complex AP-1 binds HIV-1 and MLV Gag and facilitates their budding.

Camus G, Segura-Morales C, Molle D, Lopez-Vergès S, Begon-Pescia C, Cazevieille C, Schu P, Bertrand E, Berlioz-Torrent C, Basyuk E.

Mol Biol Cell. 2007 Aug;18(8):3193-203. Epub 2007 May 30.

35.

Pancreatic cellular injury after cardiac surgery with cardiopulmonary bypass: frequency, time course and risk factors.

Nys M, Venneman I, Deby-Dupont G, Preiser JC, Vanbelle S, Albert A, Camus G, Damas P, Larbuisson R, Lamy M.

Shock. 2007 May;27(5):474-81.

PMID:
17438451
36.

Rafts are required for acetylcholine receptor clustering.

Stetzkowski-Marden F, Recouvreur M, Camus G, Cartaud A, Marchand S, Cartaud J.

J Mol Neurosci. 2006;30(1-2):37-8.

PMID:
17192619
37.

Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions.

Lopez-Vergès S, Camus G, Blot G, Beauvoir R, Benarous R, Berlioz-Torrent C.

Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14947-52. Epub 2006 Sep 26.

38.

Endotoxaemia, production of tumour necrosis factor alpha and polymorphonuclear neutrophil activation following strenuous exercise in humans.

Camus G, Nys M, Poortmans JR, Venneman I, Monfils T, Deby-Dupont G, Juchmès-Ferir A, Deby C, Lamy M, Duchateau J.

Eur J Appl Physiol Occup Physiol. 1998 Dec;79(1):62-8.

PMID:
10052662
39.

Developmental regulation of tyrosine phosphorylation of the nicotinic acetylcholine receptor in Torpedo electrocyte.

Camus G, Ludosky MA, Bignami F, Marchand S, Cartaud J, Cartaud A.

Mol Cell Neurosci. 1999 Jan;13(1):69-78.

PMID:
10049532
40.

Effects of training on exercise-induced muscle damage and interleukin 6 production.

Croisier JL, Camus G, Venneman I, Deby-Dupont G, Juchmès-Ferir A, Lamy M, Crielaard JM, Deby C, Duchateau J.

Muscle Nerve. 1999 Feb;22(2):208-12.

PMID:
10024133
41.

Possible in vivo tolerance of human polymorphonuclear neutrophil to low-grade exercise-induced endotoxaemia.

Camus G, Nys M, Poortmans JR, Venneman I, Monfils T, Deby-Dupont G, Juchmès-Ferir A, Deby C, Lamy M, Duchateau J.

Mediators Inflamm. 1998;7(6):413-5.

42.

Targeting of acetylcholine receptor and 43 kDa rapsyn to the postsynaptic membrane in Torpedo marmorata electrocyte.

Bignami F, Camus G, Marchand S, Bailly L, Stetzkowski-Marden F, Cartaud J.

J Physiol Paris. 1998 Jun-Aug;92(3-4):177-81.

PMID:
9789804
43.

Polarized sorting of nicotinic acetylcholine receptors to the postsynaptic membrane in Torpedo electrocyte.

Camus G, Jasmin BJ, Cartaud J.

Eur J Neurosci. 1998 Mar;10(3):839-52.

PMID:
9753152
44.

Mild endotoxaemia and the inflammatory response induced by a marathon race.

Camus G, Poortmans J, Nys M, Deby-Dupont G, Duchateau J, Deby C, Lamy M.

Clin Sci (Lond). 1997 Apr;92(4):415-22.

PMID:
9176042
45.

Cellular mechanisms of inflammation.

Camus G.

Mediators Inflamm. 1997;6(2):154-8. No abstract available.

46.

Piroxicam fails to reduce myocellular enzyme leakage and delayed onset muscle soreness induced by isokinetic eccentric exercise.

Croisier JL, Camus G, Monfils T, Deby-Dupon G, Fafchamps M, Venneman I, Crielaard JM, Juchmès-Ferir A, Lhermerout C, Lamy M, Deby C.

Mediators Inflamm. 1996;5(3):230-4.

47.

Myocellular enzyme leakage, polymorphonuclear neutrophil activation and delayed onset muscle soreness induced by isokinetic eccentric exercise.

Croisier JL, Camus G, Deby-Dupont G, Bertrand F, Lhermerout C, Crielaard JM, Juchmès-Ferir A, Deby C, Albert A, Lamy M.

Arch Physiol Biochem. 1996;104(3):322-9.

48.

Cellular mechanisms of inflammation liege, belgium, 10 february 1995:.

Camus G.

Mediators Inflamm. 1995;4(3):229-34. No abstract available.

49.

Are similar inflammatory factors involved in strenuous exercise and sepsis?

Camus G, Deby-Dupont G, Duchateau J, Deby C, Pincemail J, Lamy M.

Intensive Care Med. 1994 Nov;20(8):602-10. Review.

PMID:
7706577
50.

Inactivation of alpha(2)-Macroglobulin by Activated Human Polymorphonuclear Leukocytes.

Deby-Dupont G, Croisier JL, Camus G, Brumioul D, Mathy-Hartert M, Sondag D, Deby C, Lamy M.

Mediators Inflamm. 1994;3(2):117-23.

Supplemental Content

Support Center